Circulating tumor cells as a possible prognostic tool in newly diagnosed non-metastatic colorectal cancer?

Loes Scholten, Leon W.M.M. Terstappen, Job van der Palen, Walter Mastboom, Arjan Tibbe, Istvan Vermes, Marco de Groot

Research output: Contribution to journalMeeting AbstractOther research output

Abstract

Background: The presence of circulating tumor cells (CTC) is associated with poor prognosis in patients with metastatic colorectal cancer (CRC). The current study was conducted to determine if the presence of CTC prior to surgery in patients with newly diagnosed non-metastatic CRC can identify those patients at risk for disease recurrence.

Methods: In a prospective single center study 180 patients with newly diagnosed non-disseminated CRC scheduled for surgery were enrolled and followed up for a median of 41 months. CTC were enumerated with the CellSearch System in 4 aliquots of 7.5 ml of peripheral blood before undergoing surgery. The control group consisted of sixty patients with benign tumors after surgery or colonoscopy.

Results: ≥1 CTC/ 30ml of blood were detected in 9 (15%) persons of the control group, and in 41 (23%) CRC patients. From the 180 CRC patients, 44 developed recurrent disease (24%) and 38 patients (21%) died during follow up. Presence of CTC correlated with disease recurrence (p= 0.040) and death (p=0.006). Patients with CTC had a significantly decreased three year Disease Free Survival (DFS) and overall survival (OS) versus those without CTC (DFS 57%vs. 78%, p=0.018 and OS 70% vs. 80%, p=0.003%).

Conclusions: Patients with stage I-III CRC with CTC before surgery have a significantly lower 3 years DFS and OS. These findings warrant further development of technology to increased the sensitivity and specificity of CTC detection for incorporation as prognostic marker along side Duke Stage to assess which patients need adjuvant treatment.
Original languageEnglish
Pages (from-to)395-395
JournalJournal of clinical oncology
Volume30
Issue number4_suppl.
DOIs
Publication statusPublished - 19 Jan 2012
Event2012 ASCO Gastrointestinal Cancers Symposium - San Francisco, United States
Duration: 19 Jan 201221 Jan 2012

Fingerprint

Circulating Neoplastic Cells
Colorectal Neoplasms
Disease-Free Survival
Survival
Recurrence
Control Groups
Colonoscopy

Cite this

@article{7db0541c71d049b3a0918400e64d9a7f,
title = "Circulating tumor cells as a possible prognostic tool in newly diagnosed non-metastatic colorectal cancer?",
abstract = "Background: The presence of circulating tumor cells (CTC) is associated with poor prognosis in patients with metastatic colorectal cancer (CRC). The current study was conducted to determine if the presence of CTC prior to surgery in patients with newly diagnosed non-metastatic CRC can identify those patients at risk for disease recurrence.Methods: In a prospective single center study 180 patients with newly diagnosed non-disseminated CRC scheduled for surgery were enrolled and followed up for a median of 41 months. CTC were enumerated with the CellSearch System in 4 aliquots of 7.5 ml of peripheral blood before undergoing surgery. The control group consisted of sixty patients with benign tumors after surgery or colonoscopy.Results: ≥1 CTC/ 30ml of blood were detected in 9 (15{\%}) persons of the control group, and in 41 (23{\%}) CRC patients. From the 180 CRC patients, 44 developed recurrent disease (24{\%}) and 38 patients (21{\%}) died during follow up. Presence of CTC correlated with disease recurrence (p= 0.040) and death (p=0.006). Patients with CTC had a significantly decreased three year Disease Free Survival (DFS) and overall survival (OS) versus those without CTC (DFS 57{\%}vs. 78{\%}, p=0.018 and OS 70{\%} vs. 80{\%}, p=0.003{\%}).Conclusions: Patients with stage I-III CRC with CTC before surgery have a significantly lower 3 years DFS and OS. These findings warrant further development of technology to increased the sensitivity and specificity of CTC detection for incorporation as prognostic marker along side Duke Stage to assess which patients need adjuvant treatment.",
author = "Loes Scholten and Terstappen, {Leon W.M.M.} and {van der Palen}, Job and Walter Mastboom and Arjan Tibbe and Istvan Vermes and {de Groot}, Marco",
year = "2012",
month = "1",
day = "19",
doi = "10.1200/jco.2012.30.4_suppl.395",
language = "English",
volume = "30",
pages = "395--395",
journal = "Journal of clinical oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4_suppl.",

}

Circulating tumor cells as a possible prognostic tool in newly diagnosed non-metastatic colorectal cancer? / Scholten, Loes; Terstappen, Leon W.M.M.; van der Palen, Job; Mastboom, Walter; Tibbe, Arjan; Vermes, Istvan; de Groot, Marco.

In: Journal of clinical oncology, Vol. 30, No. 4_suppl., 19.01.2012, p. 395-395.

Research output: Contribution to journalMeeting AbstractOther research output

TY - JOUR

T1 - Circulating tumor cells as a possible prognostic tool in newly diagnosed non-metastatic colorectal cancer?

AU - Scholten, Loes

AU - Terstappen, Leon W.M.M.

AU - van der Palen, Job

AU - Mastboom, Walter

AU - Tibbe, Arjan

AU - Vermes, Istvan

AU - de Groot, Marco

PY - 2012/1/19

Y1 - 2012/1/19

N2 - Background: The presence of circulating tumor cells (CTC) is associated with poor prognosis in patients with metastatic colorectal cancer (CRC). The current study was conducted to determine if the presence of CTC prior to surgery in patients with newly diagnosed non-metastatic CRC can identify those patients at risk for disease recurrence.Methods: In a prospective single center study 180 patients with newly diagnosed non-disseminated CRC scheduled for surgery were enrolled and followed up for a median of 41 months. CTC were enumerated with the CellSearch System in 4 aliquots of 7.5 ml of peripheral blood before undergoing surgery. The control group consisted of sixty patients with benign tumors after surgery or colonoscopy.Results: ≥1 CTC/ 30ml of blood were detected in 9 (15%) persons of the control group, and in 41 (23%) CRC patients. From the 180 CRC patients, 44 developed recurrent disease (24%) and 38 patients (21%) died during follow up. Presence of CTC correlated with disease recurrence (p= 0.040) and death (p=0.006). Patients with CTC had a significantly decreased three year Disease Free Survival (DFS) and overall survival (OS) versus those without CTC (DFS 57%vs. 78%, p=0.018 and OS 70% vs. 80%, p=0.003%).Conclusions: Patients with stage I-III CRC with CTC before surgery have a significantly lower 3 years DFS and OS. These findings warrant further development of technology to increased the sensitivity and specificity of CTC detection for incorporation as prognostic marker along side Duke Stage to assess which patients need adjuvant treatment.

AB - Background: The presence of circulating tumor cells (CTC) is associated with poor prognosis in patients with metastatic colorectal cancer (CRC). The current study was conducted to determine if the presence of CTC prior to surgery in patients with newly diagnosed non-metastatic CRC can identify those patients at risk for disease recurrence.Methods: In a prospective single center study 180 patients with newly diagnosed non-disseminated CRC scheduled for surgery were enrolled and followed up for a median of 41 months. CTC were enumerated with the CellSearch System in 4 aliquots of 7.5 ml of peripheral blood before undergoing surgery. The control group consisted of sixty patients with benign tumors after surgery or colonoscopy.Results: ≥1 CTC/ 30ml of blood were detected in 9 (15%) persons of the control group, and in 41 (23%) CRC patients. From the 180 CRC patients, 44 developed recurrent disease (24%) and 38 patients (21%) died during follow up. Presence of CTC correlated with disease recurrence (p= 0.040) and death (p=0.006). Patients with CTC had a significantly decreased three year Disease Free Survival (DFS) and overall survival (OS) versus those without CTC (DFS 57%vs. 78%, p=0.018 and OS 70% vs. 80%, p=0.003%).Conclusions: Patients with stage I-III CRC with CTC before surgery have a significantly lower 3 years DFS and OS. These findings warrant further development of technology to increased the sensitivity and specificity of CTC detection for incorporation as prognostic marker along side Duke Stage to assess which patients need adjuvant treatment.

U2 - 10.1200/jco.2012.30.4_suppl.395

DO - 10.1200/jco.2012.30.4_suppl.395

M3 - Meeting Abstract

VL - 30

SP - 395

EP - 395

JO - Journal of clinical oncology

JF - Journal of clinical oncology

SN - 0732-183X

IS - 4_suppl.

ER -